One-carbon is receiving a seed investment

by admin
september 10, 2021

One-carbon is receiving a seed investment from its founders to strengthen the financial situation and secure continuous pre-clinical development of MTHFD2 inhibitors.

Rekommenderade artiklar

One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe

One-carbon therapeutics AB is discussing the ODIN trial with several

Our Founder Prof Thomas Helleday wins the Anders Jahre’s price in Medicine

Read the article here.

One-carbon therapeutics AB is moving into new offices

In preparation and expansion for the upcoming clinical trial, we

Menu bar